Structural and Kinetic Basis for the Rational Design of Next-Generation β-Lactamase Inhibitors
Journal of Medicinal Chemistry · 26.03.2026 · 69 (6) · 7262-7275
DOI: 10.1021/acs.jmedchem.5c03315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.03.2026. Verfasst von Shuang Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, London WC1N 1AX, U.K. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Drug Design, beta-Lactamases, Boronic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Division of Microbiology and Infectious Diseases.
Abstract (Originalsprache)
The global spread of β-lactamase-mediated resistance poses a threat to β-lactam antibiotics. Boron-based β-lactamase inhibitors (BLIs) represent a promising class of reversible covalent inhibitors, yet the molecular basis of their recognition and dissociation remains poorly understood. Using Pseudomonas-derived cephalosporinase-3 (PDC-3) as a model, we employed enhanced sampling strategies with machine learning and steady-state kinetic assays to investigate the binding and unbinding dynamics of LP06, a boronate BLI. We identify three binding pathways, governed by hydrophobic recognition motifs and a conserved arginine anchor that together steer the ligand toward the precovalent state. Sequence alignment of nearly 7000 class C β-lactamases supports the conservation of these determinants, and structural analyses suggest that R349 may act as a shared anchoring point across serine β-lactamases. Additionally, hydrogen-bonding interactions were found to delay productive binding by stabilizing nonproductive conformations. Our findings provide fundamental insights into β-lactamase inhibition and establish design principles for next-generation β-lactamase inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, London WC1N 1AX, U.K.
- Data Science and Computation Facility, Fondazione Istituto Italiano di Technologia, Via Morego 30, Genoa 16163, Italy.
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-5029, United States.
- Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-5029, United States.
- Clinician Scientist Investigator, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio 44106-1702, United States.
- Departments of Pharmacology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-5029, United States.
ORCID-Profile: Sergio Decherchi, Andrea M Hujer, Robert A Bonomo, Shozeb Haider
Förderung
- Division of Microbiology and Infectious Diseases
Zitieren
APA
Chen, S., Yu, M., Xu, M., Decherchi, S., Taracila, M. A., Hujer, A. M., Bethel, C. R., Bonomo, R. A., & Haider, S. (2026). Structural and Kinetic Basis for the Rational Design of Next-Generation β-Lactamase Inhibitors. Journal of Medicinal Chemistry, 69(6), 7262-7275. https://doi.org/10.1021/acs.jmedchem.5c03315
Vancouver
Chen S, Yu M, Xu M, Decherchi S, Taracila MA, Hujer AM, et al. Structural and Kinetic Basis for the Rational Design of Next-Generation β-Lactamase Inhibitors. Journal of Medicinal Chemistry. 2026;69(6):7262-7275. doi:10.1021/acs.jmedchem.5c03315
BibTeX
@article{Chen2026,
author = {Chen, Shuang and Yu, Muchen and Xu, Manming and Decherchi, Sergio and Taracila, Magdalena A and Hujer, Andrea M and Bethel, Christopher R and Bonomo, Robert A and Haider, Shozeb},
title = {Structural and Kinetic Basis for the Rational Design of Next-Generation β-Lactamase Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {6},
pages = {7262--7275},
doi = {10.1021/acs.jmedchem.5c03315}
}
EUVIMED